Recent studies have revealed that CD4 + T helper (Th) cells and their cytokines play a critical role in driving pathological events of VMC. 3 There is accumulating evidence showing an increased expression of interleukin 17 (IL-17), one of the signature cytokines of the Th17 cell, during viral myocarditis. 4, 5 Neutralizing IL-17 with a monoclonal antibody been previously shown to effectively protect the myocardium from CVB3-induced myocarditis. 6, 7 Based on these findings, IL-17 may be considered as a major cytokine determining the prognosis of viral myocarditis. The clinical usage of Rho kinase inhibitors is expanding in recent years, and there is evidence for its treatment for cardiovascular diseases. [8] [9] [10] Fasudil, a Rho kinase (ROCK) inhibitor, has been approved for clinical use in many countries as an effective and safe agent for the subarachnoid hemorrhage-induced cerebral vasospasm. 8, 11 Studies showed that Fasudil participated in regulation of various cytokines, including IL-17, and reversed cardiac inflammation and remodeling along with the progression of cardiovascular diseases. 8 However, the effect of Fasudil on viral myocarditis has not been reported yet.
Based on these previous findings, we hypothesized that Fasudil may be beneficial for VMC. In this report, we carried out Fasudil 
| MATERIAL S & ME THODS

| Experimental animal, cell, and virus
Male BALB/c mice (4-week old, 16.3 ± 1.3 g) were purchased from Shanghai Laboratory Animal Center, China. All mice used in this study were approved by the institutional care and use committee (IACUC) of Wenzhou Medical University and complied with NIH Guidelines.
CVB3 Nancy strain was purchased from ATCC (Manassas, VA). Hep2 cells were purchased from the Cell Bank of Shanghai Institute of Bio chemistry and Cell Biology, China. The virus was amplified in Hep2 cell and harvested for induction of the AVM model.
| AVM mouse model
All mice were randomly divided into control group (control, n = 40), viral myocarditis group treated with placebo (placebo, n = 40), and viral myocarditis treated with Fasudil treatment group (Fasudil, n = 40). Viral myocarditis was induced in mice in the placebo and Fasudil groups injected intraperitoneally (ip) with 10 5 CVB3 in 0.1 mL PBS (titer was determined with 50% tissue culture infectious dose assay). Mice in the control group were injected ip with the same dose of PBS. We defined the day of virus inoculation as day 0.
Twenty-four hours after the initial inoculation, Fasudil (5 or 10 mg
Fasudil Hydrochloride/kg/d, Selleck, Shanghai, China) was administered by ip for 14 consecutive days in the Fasudil group. Meanwhile, the control and placebo groups received the same amount of PBS.
Twenty mice were randomly selected from each group to monitor survival rate during the 14 consecutive days. We sacrificed eight surviving mice from each group on day 7 and day 14 to obtain cardiac and plasma samples. The body weight (BW) and heart weight (HW) were measured. The ratio of HW/BW was calculated as a heart function index. Plasma IL-17 concentration was measured by an enzyme-linked immunosorbent assay (ELISA). Each mouse heart was dissected into three parts: one part was for histopathological study, one part for analysis of protein expression, and one part for isolating total RNA for measurement of gene expression.
| Myocardial histopathology
Myocardial tissue was fixed in neutral buffered formalin, embedded in paraffin, and sectioned into 5-μm-thick slices. Then the slices were stained with HE (hematoxylin and eosin) solution and photographed with the EVOS FL Auto Imaging System (ThermoFisher Scientific, Grand Island, NY, USA). Two observers evaluated double-blindly the infiltration of inflammatory cells and necrotic lesions, and a third observer judged the inconsistency between the two observers. The degree of inflammatory cell infiltration and necrosis was scored as previously described, 0 = no lesion; 1 = lesion involvement <25%
area of the myocardium; 2 = lesions involvement 25%-50% area of the myocardium; 3 = lesions involvement 50%-75% area of the myocardium; and 4 =lesions involvement >75% area of the myocardium.
| Echocardiogram
On the day 7 and day 14 of the experiment, six of survived mice from the control, placebo, and Fasudil groups were randomly selected for echocardiographic examination. Briefly, mice were anesthetized intraperitoneally with a surgical cocktail containing 10 mg/ mL ketamine and 1 mg/mL xylazine at a dose of 10 mL/kg. Then Finally, the left ventricle ejection fraction (LVEF) and the fraction shortening (FS) were calculated accordingly.
| Purification of CD4 + T cells from CVB3-infected mouse heart
Isolation of single CD4 + T cells from the mice hearts according to a previously published protocol with some modifications. 12 Briefly, the left ventricle was exposed and cannulated for perfusion to remove blood in the circulation. 
| Western blotting
Proteins were extracted from the mouse hearts in RIPA buffer as the internal control to calculate relative values of viral abundance using 2 -ΔΔCt method. The sequences of primers used in this study are illustrated in Table 1 . 
| ELISA measurement of TNFα, IL-1β, and IL-17
| Statistics analysis
All the experiments were repeated at least three times unless otherwise mentioned. Numeric data are presented as mean ± SEM. The multiple Kaplan-Meier survival data were analyzed with log-rank test for trend in the GraphPad Prism 7 software (GraphPad Software
Inc., San Diego, CA, USA). The Bonferroni-corrected threshold was computed to determine the difference among groups of survival data. Other data were analyzed with Student's t test, one-way or two-way ANOVA whenever it was appropriate. Comparisons among the control, placebo, and Fasudil groups were performed, and a value of P < 0.05 was considered significant.
| RE SULTS
| Fasudil treatment improved survival of CVB3-infected mice during a 14-day follow-up study
To study whether Fasudil treatment protects mice from CVB3 infection, we started a 14-day observation on a CVB3-induced AVM Next, we examined cardiac indexes of these three groups of mice.
The ratio of heart weight over body weight (HW/BW, mg/g) was 5
in the control group ( Figure 3A , Control). The ratios increased up to 6.5 and 7 on the 7th and 14th day after CVB3 infection, respectively ( Figure 3A , Placebo). Interestingly, Fasudil treatment significantly reduced the HW/BW ratios at the both time points (Figure 3A , Fasudil).
The results of echocardiogram also showed great improvement of cardiac functions of infected mouse hearts after Fasudil treatment (Table 2) . Specially, the left ventricle ejection fraction was preserved in the Fasudil-treated group ( Figure 3B ).
Taking together, these data indicated that Fasudil treatment reduced cardiac inflammation and protected cardiac functions from CVB3 infection.
| Fasudil treatment reduced viral burden in cardiac tissues and plasma levels of proinflammatory cytokines, TNFα, and IL-1β
To monitor viral replication, we measured viral genomic RNA of CVB3
in the mouse heart and pancreas by quantitative RT-PCR. Replication of CVB3 was highly active during acute phase as relative higher viral RNA levels were recorded on day 7 than those of day 14 in the heart and pancreas ( Figure 4A , Day 7 vs Day 14), consistent with previous studies. 13, 14 Fasudil treatment obviously reduced the viral burden at both time points in these two CVB3-sensitive tissues ( Figure 4A , Placebo vs Fasudil). We also determined expression of the proinflammatory
The cumulative survival rate of mice in each group during 14-day follow-up. Mice were randomly divided into three groups with 20 mice in each group, including no viral infection (Control) and CVB3 infection followed by ip saline (Placebo) or Fasudil for 14 d. Two dosages of Fasudil treatment were administrated as indicated. The number of survival mice of each group was counted daily. Survival rate of mice treated with 10 mg/ kg Fasudil was significantly higher than those in myocarditis group F I G U R E 2 Histopathological changes in heart tissues after viral infection. Representative H&E staining images (200x) of paraffinembedded heart tissue cross-sections were shown after photographed with bright field microscopy (A). No myocardial histopathological lesions were found in the control group. Compared with the placebo group, Fasudil treatment attenuated infiltration of inflammatory cells and focal necrotic lesions in heart tissue on day 7 and day 14. Necrotic lesions (B) and inflammatory cell infiltration (C) presented in H&E stained slides were scored and presented in bar charts. The statistics were analyzed with Student's t test at each time point F I G U R E 3 Improvement of cardiac function by Fasudil treatment after CVB3 infection (A) Heart and body weight of each mouse was scaled. Then the heart weight (HW) was normalized with body weight (BW) to obtain a ratio, which was comparable among mice. Consistently, the elevated plasma levels of TNFα and IL-1β by CVB3 infection were also inhibited by Fasudil treatment ( Figure 4C ). In summary, these results indicated that Fasudil alleviated cardiac viral replication and inflammatory response in the AMV mouse model.
| Fasudil treatment inhibited CVB3 infectioninduced expression of ROCK2 and IL-17
Previous studies have suggested that expressions of ROCKs were induced in inflammatory sites. 8 To understand the underlying mechanism of Fasudil treatment on CVB3 infection, we measured both Figure 5D, pERM) , indicating the treatment was effective.
Consistent with their mRNA levels ( Figure 5A-C) , the protein levels of ROCK2 and IL-17 were significantly increased in the placebo group on both day 7 and day 14 ( Figure 5D-F) . Strikingly, treatment with Fasudil decreased these two proteins by more than 50% at both time points. IL-17 levels in the heart tissues were also measured with ELISA ( Figure 6A ), and the results were similar to that of WB ( Figure 6F ). Moreover, elevated plasma levels of IL-17 were reduced with Fasudil treatment ( Figure 6B ). These findings strongly argued that Fasudil treatment inhibited viral infection-induced ROCK2 activity and expression, resulting in reduced production of IL-17 and therein alleviating inflammatory response during AVM. 
| Fasudil treatment influenced CD4
| D ISCUSS I ON
Viral myocarditis is an inflammatory disease and one of the most important contributors to dilated cardiomyopathy worldwide. Despite the remarkable advances in diagnosis and understanding of the pathophysiological mechanisms for this disease during the past decades, a specific treatment is still unavailable. In the present study, to the best of our knowledge, we demonstrate for the first time that in the acute phase of VMC, Fasudil treatment improved the survival rate of CVB3-infected mice, alleviated the acute inflammatory histopathological lesions in the heart, and reduced viral burden of CVB3
and production of proinflammatory cytokines. Fasudil directly inhibited ROCK signaling and protein level of ROCK2 in the CVB3-infected heart. Based on these findings, it is reasonable to postulate that anti-inflammatory effect of Fasudil is an important mechanism of a potential remedy for AVM. We also confirmed that ROCK2 was the major Rho kinase induced in a mouse model of experimental AVM.
However, we were unable to distinguish which cell type(s) were responsible for the increased ROCK2 expression in the mouse heart. During AVM, the severe damage to heart tissues is not only induced by direct attacking of the virus, but also by overly activated immunological responses. 18, 19 In this study, increased IL-17 expression was shown in the placebo group compared with that in the con- C, Plasma levels of TNFα and IL-1β were determined with commercially available ELISA kits. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 attenuated cardiac injury in the CVB3-induced AVM, 7 while inhibition of ROCK2 pathway specifically reduced production of IL-17. 15, 16 It is known that Rho kinase activity levels were significantly elevated and accompanied with increased production of IL-17 in patients with systemic lupus erythematosus (SLE) and rheumatic arthritis (RA), all of which could be inhibited by blocking the ROCK pathway via STAT3-dependent mechanism. 15 In the experimental autoimmune encephalomyelitis mouse model, inhibition of the ROCK pathway attenuated demyelination and acute axonal transaction owing to deceased expression of IL-17 by Fasudil treatment. 16 In line with these findings, our study is the first to confirm that Fasudil treatment pro- 
